ARTES attends BioEurope Spring 2019

Meet us at the Bio-Europe Spring 2018 tak­ing place in Vien­na, Aus­tria March 25 -27. Volk­er Jen­zelews­ki, Direc­tor Tech­nol­o­gy  at ARTES, will be present in the One-on-One Part­ner­ing pre­sent­ing ARTES’ inno­v­a­tive range of cell line and process devel­op­ment solu­tions for bio-phar­­­ma­ceu­ti­­­cal and vac­cine prod­ucts. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a […]

SplitCore – the latest milestone in ARTES´ vaccine development offer

ARTES Biotech­nol­o­gy announces the acqui­si­tion of the unique Split­Core tech­nol­o­gy devel­oped by sci­en­tists at the Uni­ver­si­ty of Freiburg, Ger­many. Back­bone of this plat­form is a flex­i­ble inte­gra­tion and pre­sen­ta­tion of for­eign anti­gens on the sur­face of cap­sid virus like par­ti­cles (cVLP), which can be pro­duced in bac­te­ria and yeast. With its yeast based METAVAX® plat­form […]

ARTES and Minapharm joint forces

ARTES Biotech­nol­o­gy GmbH, Ger­many, and Minapharm Phar­ma­ceu­ti­cals and Chem­i­cal Indus­tries S.A.E., Egypt, joint­ly announced today the for­ma­tion of a new strate­gic busi­ness pact, offer­ing pack­et solu­tion for bio­phar­ma­ceu­ti­cal process­es .   Aim of this new strate­gic busi­ness coop­er­a­tion is to joint­ly out-license com­bi­na­tions of ARTES’ and Minapharm’s respec­tive pro­pri­etary tech­nolo­gies and prod­ucts to third par­ties […]